Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regen Biopharma ( (RGBP) ) just unveiled an announcement.
On August 5, 2025, Regen Biopharma, Inc. entered into a securities purchase agreement with Labrys Fund II LP, resulting in the issuance of a 6% convertible promissory note valued at $100,000. This agreement allows Labrys the option to convert the note into common stock, potentially impacting the company’s stock trading dynamics and financial strategy.
More about Regen Biopharma
Regen Biopharma, Inc. operates in the biotechnology industry, focusing on developing innovative treatments and therapies. The company is involved in the research and development of products aimed at addressing critical medical needs.
Average Trading Volume: 74,769
Technical Sentiment Signal: Sell
Current Market Cap: $1.63M
For a thorough assessment of RGBP stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money